How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Noorossadat Seyyedi et al., adding:
”The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Von Willebrand factor is normally made only by endothelial cells and megakaryocytes, yet some cancers switch it on.
Across 100 VWF-positive cancer lines, this study tied that aberrant expression to the mutant p53R175H, which engages the repressor NF-IB and activator GATA6 to drive VWF from the promoter.
The resulting VWF fueled cancer cell to platelet aggregates, and plakoglobin reversed the effect.”
Title: The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Authors: Noorossadat Seyyedi, Chu Shiun Lo, Parnian Alavi, Manijeh Pasdar, Nadia Jahroudi
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 4, 2026, 18:08Simon Kraler: Can the Adrenomedullin System Predict Cardiogenic Shock Before It Happens?
-
Sep 4, 2026, 17:56Maxime Dely: Why Every Blood Donation Matters
-
Sep 4, 2026, 17:28Shinya Goto: When Cardiovascular Risk Gets Lower, RCTs Get Harder
-
Sep 4, 2026, 16:55New Orleans Is Calling ASH26 Is Near
-
Sep 4, 2026, 16:48ESC Congress 2026 – My Top 20 Lipidology Highlights Shaping the Future of Cardiovascular Prevention – Pablo Corral
-
Sep 4, 2026, 16:38Felice Gragnano։ Turning Cardiovascular Risk Into Action
-
Sep 4, 2026, 16:30Lisa Littner: The Hidden Burden of Prior Authorization in Bleeding Disorder Care
-
Sep 4, 2026, 13:54Ahmad G. Alzahrani: A New Classification for Acute Pulmonary Embolism
-
Sep 4, 2026, 12:52James P. Crowley: MDS vs MPN – Understanding the Difference